Factors Responsible for Non-Compliance of Glaucoma Patients to
Topical Medications in Our Setup
Hina Khan,
Yousaf Jamal Mahsood, Nazli Gul, Omer Ilyas, Sanaullah Jan
Pak J Ophthalmol 2018, Vol. 34, No. 4
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See end of article for authors affiliations …..……………………….. Correspondence to: Yousaf
Jamal Mahsood, Assistant
Professor Glaucoma, Department of Ophthalmology, Hayatabad Medical Complex,
Peshawar. E-mail:yousaf82@hotmail.com |
Purpose: To
identify the factors affecting the compliance of glaucoma patients to topical
medical treatment in our setup. Study
Design: Cross sectional study. Place
and Duration of Study: This study was carried out at
department of clinical ophthalmology, KIOMS, Hayatabad Medical Complex, Peshawar
from 1st February 2016
till 31st July 2016. Material and Methods: Patients meeting our inclusion criteria were
recruited in this study on consecutive non-probability sampling technique.
All the patients were interviewed and the causes of non-compliance to topical
medical therapy were recorded. Stratification of non-compliance was also
analyzed with respect to age groups and gender. Sample size was calculated
using open epi software with confidence level of 95% and power of 80. Results: Total
of 179 subjects participated in this study that had been advised topical
anti-glaucoma medication. Mean age of our subjects were 51.9 ± 13.2 years with most (49.2%) of
patients in age group between 50.01 – 65.00 years. Non-compliance was
observed in 76.5% of patients with high cost of the medicines being on top of
the list (54%). Male gender and older age group were found statistically
significant to be more non-compliant. Conclusion: High
cost of topical anti-glaucoma medications is the leading cause of
non-compliance in our setup. Keywords: Glaucoma,
Non-compliance, Non-adherence. |
Glaucoma is the second leading cause of bilateral blindness
worldwide1. Chronic open angle glaucoma
is reported as leading cause of bilateral blindness in African Americans1. It
affects 2% of the population above 40years and up to 10% above 80years of age
globally2. It is estimated that about
2.47 million are affected by chronic open angle glaucoma in USA, of whom 5.3%
are blind bilaterally1. The blindness
caused by glaucoma can be prevented, if appropriate treatment with ocular
hypotensive medicines is initiated on time. Consistent IOP lowering by these
medications is associated with reduced risk of optic nerve damage and
preventing its progression1. However
this requires early diagnosis of the disease as well as compliance with
appropriate ocular hypotensive medications and access to proper eye care1,3. The term compliance has been replaced by
more specific terms i.e. adherence and persistence. “Adherence is a measure of
degree to which patient follows prescribed instruction during a defined period
of time”. “Persistence is defined as the criterion that evaluates the time
until the patient first discontinues use of medication”1. Chronic and initially asymptomatic diseases
like glaucoma are subject to patients’ poor adherence and persistence and have
a higher rate of visual loss in affected individuals4,5.
The risk factors for non compliance with antiglaucoma medications
remain poorly understood and defined6.
Many studies have been carried out in west to determine the factors responsible
for noncompliance to topical glaucoma therapy. There are three different
techniques which are used for data collection regarding poor adherence and
persistence to anti glaucoma medications. These are Patient self report,
Pharmacy refill data, and electronic monitoring1,4.
The factors presumed to be responsible for non adherence include
cost, tolerability, difficulty in administering drops, denial, lack of
education7, travel issues, old age, forgetfulness, careless
attitude, patient physical disability, adverse effects of the drug,
inconvenient frequency8 and lack of symptoms without treatment1,4. According to one study, 44% patients were
compliant and 35% were non compliant4 and
the remaining were lost to follow up. According to another study 84%, patients
were non compliant, and factors responsible were living alone, lacking an
escort and transport issues. According to another study, the most prevalent
barriers were belief that there was no problem with one’s eyes (44.4%) and lack
of escort (19.7%)7.
As far as cost is concerned, 41% had difficulty paying for their
medications and 11.5% who had paid fully for the medications themselves stated
that the expenses of medications on occasions prevented them from filling their
prescription and that 76% of patients had an income of less than 30,000 USD/year6.
Recent observational studies showed that those with poor health
literacy were 75% more likely to miss eye drops at least two times a month6.
Lack of accessibility for a patient living in a remote area is an
another major factor, a recent study showed that those who had no car were 2.08
times more likely to be noncompliant then who had a transport1.
A study showed a variable influence of age on compliance, out of
273 patients, 189(69.3%) were compliant (mean age 58.1+/-1.4) and 84(30.7%)
were noncompliant (mean age 53.7+/- 1.8)1.
The
rationale behind this study is that most of the studies or data reported are
from developed countries and no data exists regarding factors responsible for
noncompliance to glaucoma medications in Pakistan. It is obvious that there are
a lot of social differences including literacy rate, economical, cultural and
environmental differences between developed countries and our region. Keeping
these differences in our mind, we expect that the factors affecting compliance
to anti glaucoma medication may be different in our community than the
developed countries. We also presume that some of factors mainly involved in
anti glaucoma compliance in our country may be responsible with different
magnitude and frequency compared to developed countries. Therefore, we designed
this study to identify the factors responsible for noncompliance of topical
anti glaucoma medications in our community. The results will be discussed with
public health individuals and health care providers to minimize the problems
related to noncompliance and to reduce the burden of glaucoma blindness.
MATERIAL AND METHODS
This study was carried out at
department of clinical ophthalmology, KIOMS, Hayatabad Medical Complex,
Peshawar from 1st February
2016 till 31st July 2016. It was a cross sectional study using consecutive, convenient sampling. There were 179 patients included
in the study.
Inclusion criteria were: patients with established diagnosis of
open angle glaucoma, primary open angle glaucoma (POAG) and pseudoexfoliation (PXE)
glaucoma patients above 40 years only, all cases who had been prescribed anti
glaucoma medications. both out-patients and in-patients and post trab patients
of atleast 3 months duration who has been advised and were using topical anti
glaucoma medications.
Exclusion criteria were: any other type of glaucoma not fulfilling
the inclusion criteria---Steroid induced glaucoma, Primary angle closure glaucoma,
secondary angle closure glaucoma, neovascular glaucoma, lens induced glaucoma,
congenital glaucoma, juvenile glaucoma, traumatic glaucoma, increase IOP secondary
to any major ocular surgery, patients
having psychiatric disorders.
All patients were diagnosed and reviewed on the basis of history
clinical examination (fundoscopy, gonioscopy and IOP measurements) and relevant
investigations by consultants of our department. Approval was obtained from
hospital research and ethical committee before initiating the study. Informed
verbal consent was taken after explaining to the patients the purpose and
benefits of the study and with the permission that the study was only for data
review and publication followed by a thorough interview by me. All the information
taken from the patient was recorded on a pre designed proforma on the spot.
Non Compliance was defined as Interruption of antiglaucoma eye
drops use for at least 5 consecutive days or missing at least 10 doses at
various occasions in 30 days or no use of the medications at all since
prescribed.
Common factors of non-compliance which were studied included; High Cost or non-affordability:
Patients were asked regarding financial burden due to the cost of the
anti-glaucoma medications and if the patient considered it costly they will be
taken as a financial burden. Poor health
literacy: patients who did not know that glaucoma can lead to permanent
blindness. Lack of Accessibility: patients
living in a remote area where their residence is at a distance of more than 10
km from a specialist health care facility (teaching hospital, DHQ, THQ), making
availability of drugs and doctors difficult. The patients were interviewed
directly and their current place of residence was taken as a reference. Their
responses to the above mentioned factors of non-compliance were recorded on a
designed performa.
Data
was analyzed by SPSS version 23. Presentation of results was done by charts and
tables. Categorical variable like high cost, poor health literacy, old age and lack
of accessibility were presented as frequencies whereas numerical variable like
age was presented as mean SD. Noncompliance and leading factors was stratified
among age and gender to see the effect modifiers.
RESULTS
The study comprised a total of 179 patients diagnosed with
glaucoma who had been advised topical anti glaucoma medications for treatment. The
mean age of the patients of the whole study population was 51.9 ± 13.2
years. The patients were distributed with regards to different ages into four
groups; 20 to 35 years, 36 to 50 years,
51 to 65 years and 66 years and above. It was observed that there were 11.2% patients
in the first age group, 29.6% in second, 49.2% in the third and 10.1% in the
fourth age group respectively (Table 1).
With regards to gender, we had 48.6% males and 51.4% females. As
per operational definitions, we observed that non-compliance to topical anti
glaucoma medication was observed in 76.5% of patients. The most common factor
leading to non-compliance in our study was found to be high cost in
Table 1: Age
Wise Distribution (n = 179).
Mean Age |
51.98±12.35
years |
|
Age Group |
Frequency
(n) |
Percentage
(%) |
20 – 35 years |
20 |
11.2 |
36 – 50 years |
53 |
29.6 |
51 – 65 years |
88 |
49.2 |
>65 years |
18 |
10.1 |
54.0% of non compliant
patients followed by poor health literacy in 44.5% and lack of accessibility to
drugs in 19% of patients (Table 2).
Table 2: Common Factors Leading to Non Compliance
(n = 179).
|
Frequency |
Percentage |
High
Costa |
||
Yes No Total |
74 63 137 |
54 46 100 |
Poor
Health Literacya |
||
Yes No Total |
61 76 137 |
44.5 55.5 100 |
Lack
of Accessibility to Drugsa |
||
Yes No Total |
26 111 137 |
19 81 100 |
a. Non Compliance to Antiglaucoma Drugs = Yes
On stratifying
the non compliance with regards to gender a statistically significant difference
was found between males & females. Males tend to be more non compliant than
females p value 0.001 (Table3).
On stratifying
the non-compliance with regards to different age groups a statistically
significant difference was found among various age groups. Older age tends to
be more non compliant p value 0.049 (Table 4).
We also
stratified individual factors leading to non-compliance with regards to gender.
While applying chi square we didn’t find any significant difference with
regards to gender for each high cost (p value 0.39), Poor health literacy (p
value 0.525) and Lack of accessibility to drug (p 0.533).
We also stratified
individual factors leading to non compliance with regards to different age
groups. While applying chi square we didn’t find any
Table 3: Gender
Wise Comparison of Non Compliance (n = 179).
Gender of Patient Non Compliance to Antiglaucoma Drugs |
|||||
|
Non
Compliance to Antiglaucoma Drugs |
Total |
|||
Yes |
No |
||||
Gender of Patient |
Male |
Count |
76 |
11 |
87 |
% within Gender of Patient |
87.4% |
12.6% |
100.0% |
||
Female |
Count |
61 |
31 |
92 |
|
% within Gender of Patient |
66.3% |
33.7% |
100.0% |
||
Total |
Count |
137 |
42 |
179 |
|
% within Gender of Patient |
76.5% |
23.5% |
100.0% |
Chi square applied, p = 0.001
Table 4: Age
Groups Wise Comparison of Non Compliance (n = 179).
Non
Compliance to Anti-glaucoma Drugs |
Total |
|||
|
Yes |
No |
||
Age Groups |
20 to 35 years |
16 |
4 |
20 |
36 to 50 years |
36 |
17 |
53 |
|
51 to 65 years |
67 |
21 |
88 |
|
66.years & above |
18 |
0 |
18 |
|
Total |
137 |
42 |
179 |
Chi square applied, p = 0.049
significant difference with
regards to different age groups for each high cost (p value 0.33), Poor health
literacy (p value 0.163) and Lack of accessibility to drug (p 0.638).
DISCUSSION
Glaucoma continues to be a challenging disease in some patients, as
the diseases continues to progress in spite of a controlled IOP. Vascular
phenomenon and its role in glaucoma has been significantly discussed8,
as significant data has been presented to support its role in the development
of optic neuropathy. In the light of these descriptions, stress should be made
on establishing the hemodynamic profile of glaucoma treatments, as well as their
role in IOP.
In order to have a significant effect on ocular blood flow, any
topical glaucoma drug should not only have the ability to penetrate the
anterior surface of the eye, it should also attain the critical levels to
attain the required physiological effects on local hemodynamics. All of the glaucoma
therapies have the inherent potential to effect the vascular smooth muscle9.
To preserve vision, glaucoma patients need to have a long term
treatment plan and carefully planned follow-up care. Though glaucoma is
considered a preventable cause of blindness, multiple studies, in both
developed and underdeveloped parts of the world, have shown that still there
are multiple causes of failure to prevent blindness from glaucoma; the
commonest being inadequate access to eye care resources and failure to adhere
to the treatment.
Identification of partial
compliance or non compliance to the prescribed medications is determined by
following the difference between the patient’s dosing history and the
prescribed dosing regimen. However, with the advent of electronic monitoring
method, first used in 1977, the identification of partial and non-compliance
has become somewhat simple10. Before this, other methods of
determining compliance like counts of returned, untaken doses; questionnaires;
histories; diaries; assays of drug concentration in plasma11; and
audits of prescription refills — were not very accurate as they only gave an
idea of dosing history that indicated only dosing omissions but gave no
information about the number of doses that were omitted12.
However, there are studies
that show varying results where providers estimate can be poorly related to the
adherence13 and the self-reporting of the patient can be better
related to the measure of adherence14.
Our study showed that 76.5% of the total patients were
noncompliant to their glaucoma drugs in contrast to another study of 2004
whereby only 60% of the patients were found to be noncompliant15.Such a
high rate of noncompliance is attributed to multiplicity of drugs as such
patients are more likely to have problems in remembering their drugs, increased
incidence of side effects compelling the patients to restrict their medications
and inconvenience of timings to dosing. So to avoid these problems, stress
should be laid upon simplifying the regimen as much as possible. This principle
of simplifying the regimen has worked very well in other diseases in terms of
improving the adherence16. Our study shows levels of non compliance to
glaucoma medication that are both higher17 and lower13
than the previous reports. This may be partly attributed to the differences in
study populations.
The adherence rate for patients who are taking drugs for various
chronic diseases varies from 43-78%12. So far, no standard criteria
for adherence rates in clinical trials has been defined, however, an adherence
rate of more than 80% is considered acceptable.
The findings of our study are generally consistent with the
literature. In comparison to several other studies18,19, health
literacy appeared to be associated with compliance in our sample. However, this
may be attributed to the fact that we didn’t include frequency of dosing as a
measure which would have been a more sensitive measure.
Recently, behavioral and lifestyle issues have been identified as
factors with significant impact on adherence to glaucoma drugs20. Many of
these factors may be modifiable and a thorough understanding of these issues
may help us in a better understanding of the long-term management of glaucoma
medication adherence7. Similarly, co-existing chronic health issues
may also have a significant effect on medication adherence21.
Different studies have measured adherence differently. They have
either used the direct evaluation or the indirect evaluation13. Direct
evaluation involves direct observation of the patient by the observer while
taking the dose or assessing the level of the drug or its metabolite in the
blood, urine or stool. Indirect evaluation is assessment of the adherence by
indirect indicators like pharmacy information, clinical response to the
regimen, patients diary etc. still there is no consensus as to the better
method of assessment as different studies have shown different results; most
studies showing that the observers are poor predictors of the patients
compliance and patients consistently over-represent their degree of adherence12,22.
The adherence to ophthalmic drugs should be considered a different
entity and similarly the dynamics of ophthalmic drugs administration are
different from that of the oral drugs. In a study by Vrijens and coworkers23,
the dynamics of ophthalmic drug
administration have been staged as the acceptance of the therapy, persistency
in administering the drugs, and the ability to “execute” or correctly
administer the drops. As compared to the administration of ophthalmic drugs,
the administration of oral drugs is a somewhat straight forward phenomenon
unless the patient is having a psychomotor deficit and can be executed without
any observation. In contrast to the oral medications that can be easily taken,
the self-administration of ophthalmic drugs is somewhat cumbersome and
challenging and depends upon the optimum coordination between the psychomotor
components of the human body. The addition of another drug to an ophthalmic
regimen can make the process more difficult to execute24. Poor
adherence is compounded if the drop is not appropriately placed in the eye. The
issue can be made worse if the patient is an elderly person with multiple
comorbidities like diabetes mellitus, hypertension, cardiac issues and
osteoporosis.
However, those patients who were aware of the nature and course of
the disease and the potential complications were found to be more compliant. Various
psychological diseases like depression may also have an impact on compliance13.
Increasing the complexity of doses may have a negative impact on compliance24.
However, various studies failed to establish an association between adherence
and side effects of the drugs13, 4.
The role of the prescribing doctor should never be under-rated in
increasing the compliance to the medications as efficient counselling keeping
all the impacting factors in to consideration can have a major impact on the
level of compliance12,13,22.
Currently there is a paucity of research examining intervention
strategies to enhance glaucoma medication adherence. While doctor-patient
communication strategies and increased patient education have been emphasized
and shown to be effective13, examinations of health promotion-based
efforts are also other strategies worthy of investigation in this area given
the link between medication adherence and health behaviors.
However,
certain studies have shown that input in preventive and promotional medicine
whereby patients are educated about the nature, course and potential
complications of the disease have shown promising results in terms of long term
adherence especially in people with chronic health conditions25. So more
efforts should be put into designing such preventive and health education
programs to address the issue of non-adherence to anti glaucoma medications.
But these efforts should be based on a more comprehensive understanding of the
factors that lead to non-compliance to anti-glaucoma medications.
CONCLUSION
We
found that more than 2/3rd of glaucoma patients are non-compliant to
topical treatment and the leading cause is non-affordability in our setup.
Author’s affiliation
Dr. Hina Khan
MBBS, FCPS, Trainee Registrar
Department of ophthalmology, Hayatabad Medical Complex, Peshawar.
Dr. Yousaf Jamal Mahsood
MBBS, FICO (UK), FRCS (Glasg), FCPS
Assistant Professor Glaucoma,
Department of ophthalmology, Khyber Medical Girls college,
Hayatabad Medical Complex, Peshawar.
Dr. Nazli Gul
MBBS, FCPS
Department of ophthalmology,
Kyber Teaching Hospital, Peshawar.
Dr. Omer Ilyas
MBBS, FICO, FCPS, FRCS (Glasg), Trainee Medical Officer
(Vitreoretina)
Department of ophthalmology, Hayatabad Medical Complex, Peshawar.
Dr. Sanaullah Jan
MBBS, FRCS (Glasg), FRCS (Edin), FCPS, Professor of vitreoretina
Department of ophthalmology, Khyber Girls Medical college,
Hayatabad Medical Complex, Peshawar.
Role of Authors
Dr. Hina Khan
Concept and Design, Data Collection, Writing of manuscript.
Dr. Yousaf Jamal Mahsood
Literature Review, Critical review, Data analysis.
Dr. Nazli Gul
Data Collection, Writing of manuscript.
Dr. Omer Ilyas
Writing of Manuscript, Critical Review.
Dr. Sanaullah Jan
Critical review, Concept and Design.
REFERENCES
1.
Gwira J, Vistamehr S, Shelsta H, Bashford K, Forster S, Palmisano
P, et al. Factors associated with
failure to follow up after glaucoma screening. Am Acad Ophthalmol. 2006; 113: 1315-1319.
2.
Kanski JJ, Bowling B (eds). Glaucoma: Chapter 10. In: Clinical ophthalmology, 7th ed, Elsevier,
London, 2011: 311-99.3.
3.
Quigley H, Friedman D, Hahn S. Evaluation of practice patterns for the care of open angle
glaucoma compared with claims data .Am Acad Ophthalmol. 2007; 114: 1599_1606.
4.
Schwartz G, Quigley H. Adherence and persistence with glaucoma therapy. Surv Ophthalmol.
2008; 53: S57_S68.
5.
Muir K, Santiago_turla C, Stirnett S, Herndon L, Allingham R,
Challa P, et al. Health literacy and
adherence to glaucoma therapy. Am J Ophthalmol. 2006; 142: 223-226.
6.
Tsai J. A
comprehensive perspective on patient adherence to topical glaucoma therapy. Am
Acadophthalmol. 2009; 116: S30_S36.
7.
Lee B, Sathyan P, John R, Singh K, Robin A. Predictors of and barriers associated with poor follow up in
patients with glaucoma in south India. Arch Ophthalmol. 2008; 126 (10): 1448-1454.
8.
Weinreb RN, Harris A, eds. Ocular Blood Flow in Glaucoma: The 6th Consensus Report of the
World Glaucoma Association. Amsterdam: Kugler Publications; 2009: 1-159. 11.
9.
Costa VP, Harris A, Stefánsson E. The effects of antiglaucoma and systemic medications on ocular
blood flow. Prog Retin Eye Res. 2003; 22: 769-805.
10.
Kass MA, Meltzer DW, Gordon M. A miniature compliance
monitor for eye drop medication. Arch. Ophthalmol. 1984; 102: 1550–54.
11.
Podsadecki TJ, Vrijens BC,
Tousset EP, Rode RA, Hanna GJ. “White coat compliance” limits the reliability of
therapeutic drug monitoring in HIV-1-infected patients. HIV Clin. Trials, 2008;
9: 238–46.
12.
Osterberg L, Blaschke T. Adherence to medication. N.
Engl. J. Med. 2005; 353: 487–97.
13.
Okeke CO, Quigley, Jampel HD. Adherence with topical glaucoma medication monitored
electronically. The travatan dosing aid study, Ophthalmology, 2009; 116 (2): 191–199.
14.
Sleath B, Blalock SJ, Stone JL. Validation of a short version of the glaucoma medication
self-efficacy questionnaire, British Journal of Ophthalmology, 2012; 96 (2): 258–262.
15.
Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications,”
Ophthalmology, 2006; 113 (3): 431–436.
16.
Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance a
meta-analysis. Medical Care, 1998; 36 (8): 1138–1161.
17.
Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and
adjunctive medication use. Am J Ophthal,
2007; 144 (4): 533–540.
18.
Pappa C, Hypthantis T, Pappa S, et al. Psychiatric manifestations and personality traits associated with
compliance with glaucoma treatment. Journal of Psychosomatic Research, 2006; 61:
609–617.
19.
MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open-angle Glaucoma.
Br J Ophthalmol. 1983; 67: 46–49.
20.
Friedman D, Okeke CO, Jampel H, et al. Risk factors for poor adherence to eye drops in electronically
monitored patients with glaucoma. Ophthalmology, 2009; 116: 1097–1105.
21.
Heisler M, Faul J, Hayward R, Langa K, Blaum C, Weir D. Mechanisms for racial and ethnic disparities in glycemic control
in middle-aged and older Americans in the health and retirement study. Archives
of Internal Medicine, 2007; 167: 1853–1860.
22.
Friedman DS, Quigley HA, Gelb L, Tan J, Margolis J, Shah SN, et
al. Using Pharmacy Claims Data to
Study Adherence to Glaucoma Medications: Methodology and Findings of the
Glaucoma Adherence and Persistency Study (GAPS) Invest Ophthalmol Vis Sci.
2007; 48: 5052–7.
23.
Vrijens BB, Vincze G, Kristanto P, Urquhart J Burnier M. Adherence to Prescribed Anti-Hypertensive Drug Treatments:
Longitudinal study of electronically compiled dosing histories. Br Med J. 2008;
336: 1114–7.
24.
Robin AL, Covert D.
Does Adjunctive Glaucoma Therapy Affect Adherence to the Initial Primary
Therapy? Ophthalmology, 2005; 112: 863–8.
25.
Berkley-Patton J, Goggin K, Liston R, Bradley-Edwin A. Adapting effective narrative-based HIV prevention interventions to
increase minorities' engagement in HIV/AIDS services. Health Communication,
2009; 24: 199–209.